JP2019504901A - ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター - Google Patents

ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター Download PDF

Info

Publication number
JP2019504901A
JP2019504901A JP2018561928A JP2018561928A JP2019504901A JP 2019504901 A JP2019504901 A JP 2019504901A JP 2018561928 A JP2018561928 A JP 2018561928A JP 2018561928 A JP2018561928 A JP 2018561928A JP 2019504901 A JP2019504901 A JP 2019504901A
Authority
JP
Japan
Prior art keywords
methyl
pyridine
carboxamide
thieno
ylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504901A5 (OSRAM
Inventor
クレイグ ダブリュー リンズリー
クレイグ ダブリュー リンズリー
ピー ジェフリー コーン
ピー ジェフリー コーン
ダレン ダブリュー エンガーズ
ダレン ダブリュー エンガーズ
カトリーナ エイ ボリンジャー
カトリーナ エイ ボリンジャー
ジュリー エル エンガーズ
ジュリー エル エンガーズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2019504901A publication Critical patent/JP2019504901A/ja
Publication of JP2019504901A5 publication Critical patent/JP2019504901A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018561928A 2016-02-16 2017-02-16 ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター Pending JP2019504901A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US62/296,012 2016-02-16
US201662402438P 2016-09-30 2016-09-30
US62/402,438 2016-09-30
PCT/US2017/018140 WO2017143041A1 (en) 2016-02-16 2017-02-16 Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Publications (2)

Publication Number Publication Date
JP2019504901A true JP2019504901A (ja) 2019-02-21
JP2019504901A5 JP2019504901A5 (OSRAM) 2020-03-26

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561928A Pending JP2019504901A (ja) 2016-02-16 2017-02-16 ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター

Country Status (15)

Country Link
US (1) US11111251B2 (OSRAM)
EP (1) EP3416639B1 (OSRAM)
JP (1) JP2019504901A (OSRAM)
KR (1) KR20180110132A (OSRAM)
CN (1) CN109069491A (OSRAM)
AU (1) AU2017221404A1 (OSRAM)
BR (1) BR112018016689A2 (OSRAM)
CA (1) CA3014791A1 (OSRAM)
CL (1) CL2018002335A1 (OSRAM)
EA (1) EA201891854A1 (OSRAM)
IL (1) IL261058A (OSRAM)
MA (1) MA44253A (OSRAM)
MX (1) MX385975B (OSRAM)
PH (1) PH12018501731A1 (OSRAM)
WO (1) WO2017143041A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526566A (ja) * 2016-09-02 2019-09-19 スヴェン・ライフ・サイエンシズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーター

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
RS64722B1 (sr) * 2017-06-20 2023-11-30 Takeda Pharmaceuticals Co Heterociklično jedinjenje i njegova upotreba kao pozitivnog alosteričkog modulatora holinergičkog muskarinskog m1 receptora
CN110709401B (zh) * 2017-06-20 2023-06-13 武田药品工业株式会社 杂环化合物
CN118063442A (zh) 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
AU2018354969B2 (en) * 2017-10-27 2020-09-17 Suven Life Sciences Limited Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
KR20200081424A (ko) 2017-10-31 2020-07-07 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
CN111788182B (zh) 2018-02-02 2023-09-26 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
WO2019241467A1 (en) * 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US12162864B2 (en) 2018-09-28 2024-12-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3858828A4 (en) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
WO2020086864A1 (en) 2018-10-24 2020-04-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
WO2021067696A1 (en) 2019-10-04 2021-04-08 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531901A (ja) * 2000-04-28 2003-10-28 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン性アゴニスト
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
JP2013514358A (ja) * 2009-12-17 2013-04-25 メルク・シャープ・エンド・ドーム・コーポレイション キノリンアミド化合物ｍ１受容体陽性アロステリックモデュレータ
WO2015190564A1 (ja) * 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE226208T1 (de) 1999-03-09 2002-11-15 Upjohn Co 4-oxo-4,7-dihydro-thieno(2,3-b)pyridin-5- carboxamide als antivirale mittel
KR100614900B1 (ko) 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6271758B2 (ja) 2014-01-22 2018-01-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フルオロ−ナフチル誘導体
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
KR102017786B1 (ko) 2016-09-02 2019-09-03 수벤 라이프 사이언시스 리미티드 무스카린 m1 수용체 포지티브 알로스테릭 조절제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531901A (ja) * 2000-04-28 2003-10-28 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリン性アゴニスト
JP2013514358A (ja) * 2009-12-17 2013-04-25 メルク・シャープ・エンド・ドーム・コーポレイション キノリンアミド化合物ｍ１受容体陽性アロステリックモデュレータ
WO2012158474A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
WO2015190564A1 (ja) * 2014-06-13 2015-12-17 武田薬品工業株式会社 含窒素複素環化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526566A (ja) * 2016-09-02 2019-09-19 スヴェン・ライフ・サイエンシズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーター

Also Published As

Publication number Publication date
BR112018016689A2 (pt) 2019-02-12
WO2017143041A1 (en) 2017-08-24
IL261058A (en) 2018-10-31
CL2018002335A1 (es) 2019-02-01
US11111251B2 (en) 2021-09-07
MX385975B (es) 2025-03-18
AU2017221404A1 (en) 2018-08-23
EA201891854A1 (ru) 2019-01-31
EP3416639A1 (en) 2018-12-26
EP3416639B1 (en) 2022-06-08
PH12018501731A1 (en) 2019-06-17
KR20180110132A (ko) 2018-10-08
US20210230180A1 (en) 2021-07-29
CN109069491A (zh) 2018-12-21
CA3014791A1 (en) 2017-08-24
EP3416639A4 (en) 2019-07-03
MA44253A (fr) 2018-12-26
MX2018009952A (es) 2018-11-29

Similar Documents

Publication Publication Date Title
JP2019504901A (ja) ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター
JP7038414B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
US10899759B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M1
EP3534901B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7016471B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN110891569A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN109862893B (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
KR20200081424A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
JP7097623B2 (ja) ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
CN111788182A (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US20190330226A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US20200131180A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US20200131159A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CN111433212A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CN111406058A (zh) 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
US20180086776A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US11851406B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US12065433B2 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor M1
HK40014595A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
HK40014595B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210908